Inhibitor Therapeutics (INTI) Return on Capital Employed (2013 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Return on Capital Employed came in at 216.84% in Q1 2026, down 14577.0% YoY from N/an in Q1 2025, and down 30.16% on a QoQ basis from 166.59% in Q4 2025.
Inhibitor Therapeutics (INTI) Return on Capital Employed (2013 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 14 years of Return on Capital Employed data on file, last reported at 216.84% in Q1 2026.
- Quarterly Return on Capital Employed fell 14577.0% year-over-year to 216.84% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 216.84% (down 14577.0% YoY) and the FY2025 annual result came in at 102.7%, down 4739.0% from the prior year.
- Return on Capital Employed retreated to 216.84% in Q1 2026, from 166.59% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 32.61% in Q1 2022 to a low of 216.84% in Q1 2026.
- A 5-year average of 51.56% and a median of 43.21% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 25000 bps — and 2024, when it slumped 2465 bps.
- Tracing INTI's Return on Capital Employed over 5 years: stood at 12.32% in 2022, then tumbled by 221 bps to 39.53% in 2023, then slumped by 72 bps to 68.19% in 2024, then plunged by 144 bps to 166.59% in 2025, then tumbled by 30 bps to 216.84% in 2026.
- The last three Return on Capital Employed figures came in at 216.84% (Q1 2026), 166.59% (Q4 2025), and 104.71% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 7.88% |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | -391.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -216.84% |
| Dec 31, 2025 | -166.59% |
| Sep 30, 2025 | -104.71% |
| Jun 30, 2025 | -90.19% |
| Mar 31, 2025 | -71.07% |
| Dec 31, 2024 | -68.19% |
| Sep 30, 2024 | -50.92% |
| Jun 30, 2024 | -45.55% |
| Mar 31, 2024 | -43.21% |
| Dec 31, 2023 | -39.53% |
| Sep 30, 2023 | -26.27% |
| Jun 30, 2023 | -17.85% |
| Mar 31, 2023 | -10.54% |
| Dec 31, 2022 | -12.32% |
| Sep 30, 2022 | 25.37% |
| Jun 30, 2022 | 29.29% |
| Mar 31, 2022 | 32.61% |
| Dec 31, 2021 | 53.88% |
| Sep 30, 2021 | 73.97% |
| Jun 30, 2021 | 141.03% |